Literature DB >> 9059891

Killer cell receptors: keeping pace with MHC class I evolution.

N M Valiante1, K Lienert, H G Shilling, B J Smits, P Parham.   

Abstract

NK cells express receptors that bind to polymorphic determinants of MHC class I heavy chains. MHC ligands vary greatly between mammalian species, and the use of distinct molecular families of NK cell receptors by humans and mice suggests that the receptors too can be evolving rapidly. The KIR (killer cell inhibitory receptor) family of receptors are found in primates and recognize class I epitopes that are of relatively recent origin in primate evolution. Therefore, KIR molecules have probably evolved class I receptor function more recently than C-type lectins, which are represented in both humans and mice. Individual humans express NK cell receptors for which they have no class I ligand, demonstrating a looseness in the coupling of expression between the receptors and their ligands. However, study of a single donor suggests that every NK cell expresses at least one inhibitory receptor for a self-HLA class I allotype, consistent with the missing self hypothesis. Thus the NK-cell receptor-class I interaction appears to control the NK-cell repertoire during ontogeny of the individual and has the potential to be a selective factor influencing both MHC class I and NK cell receptor diversity in the evolution of populations and species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059891     DOI: 10.1111/j.1600-065x.1997.tb00948.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  22 in total

Review 1.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Natural killer cell tolerance: control by self or self-control?

Authors:  Baptiste N Jaeger; Eric Vivier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 3.  Natural killer cells: integrating diversity with function.

Authors:  Kuldeep Cheent; Salim I Khakoo
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

Review 4.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  A cold-blooded view of adaptive immunity.

Authors:  Martin F Flajnik
Journal:  Nat Rev Immunol       Date:  2018-07       Impact factor: 53.106

6.  Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors.

Authors:  M Valés-Gómez; H T Reyburn; R A Erskine; J Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Differential Induction of IFN-α and Modulation of CD112 and CD54 Expression Govern the Magnitude of NK Cell IFN-γ Response to Influenza A Viruses.

Authors:  Lisa M Kronstad; Christof Seiler; Rosemary Vergara; Susan P Holmes; Catherine A Blish
Journal:  J Immunol       Date:  2018-08-24       Impact factor: 5.422

8.  High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles.

Authors:  Kathleen A Houtchens; Robert J Nichols; Martha B Ladner; Hannah E Boal; Cristina Sollars; Daniel E Geraghty; Lee M Davis; Peter Parham; Elizabeth A Trachtenberg
Journal:  Immunogenetics       Date:  2007-04-27       Impact factor: 2.846

9.  Evidence for balancing selection acting on KIR2DL4 genotypes in rhesus macaques of Indian origin.

Authors:  Jeroen H Blokhuis; Marit K van der Wiel; Gaby G M Doxiadis; Ronald E Bontrop
Journal:  Immunogenetics       Date:  2009-06-09       Impact factor: 2.846

10.  Chain-terminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3.

Authors:  Lihui Luo; Zeying Du; Surendra K Sharma; Rebecca Cullen; Stephen Spellman; Elaine F Reed; Raja Rajalingam
Journal:  Immunogenetics       Date:  2007-07-24       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.